Generation Bio Co. (GBIO) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.41
↓-66% vs avg
5yr avg: 1.22
30Y Low0.5·High2.9
ROE
↑
-91.0%
↑-44% vs avg
5yr avg: -63.2%
30Y Low-95%·High-37%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GBIO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Generation Bio Co. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $36M | $71M | $106M | $228M | $399M | $773M | — | — |
| Enterprise Value | $53M | $88M | $138M | $217M | $104M | $710M | — | — |
| P/E Ratio → | -0.27 | — | — | — | — | — | — | — |
| P/S Ratio | 1.81 | 3.55 | 18.02 | — | — | — | — | — |
| P/B Ratio | 0.41 | 0.82 | 0.52 | 0.81 | 1.04 | 2.88 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
GBIO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.42 | 23.35 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
GBIO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Generation Bio Co. earns an operating margin of -715.8%. Operating margins have expanded from -2346.9% to -715.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -91.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — | — | — | 100.0% |
| Operating Margin | -715.8% | -715.8% | -2346.9% | — | — | — | — | -103594.4% |
| Net Profit Margin | -661.9% | -661.9% | -2144.5% | — | — | — | — | -99452.8% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -91.0% | -91.0% | -52.1% | -41.1% | -36.7% | -95.1% | — | — |
| ROA | -43.5% | -43.5% | -33.7% | -32.0% | -30.9% | -47.9% | -96.0% | -42.9% |
| ROIC | -63.2% | -63.2% | -41.1% | -59.1% | -61.1% | -133.0% | — | — |
| ROCE | -53.6% | -53.6% | -40.0% | -34.6% | -32.2% | -51.4% | -113.3% | -48.5% |
GBIO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $17M ($94M total debt minus $76M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.09 | 1.09 | 0.48 | 0.29 | 0.21 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.20 | 0.15 | -0.04 | -0.77 | -0.23 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -31.08 | -2382.02 | -137.25 | — | — |
GBIO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Generation Bio Co.'s current ratio of 5.50x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 14.99x to 5.50x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.50 | 5.50 | 6.83 | 14.99 | 20.16 | 23.86 | 1.98 | 11.74 |
| Quick Ratio | 5.50 | 5.50 | 6.83 | 14.99 | 20.16 | 23.86 | 1.98 | 11.74 |
| Cash Ratio | 5.28 | 5.28 | 6.62 | 14.57 | 19.95 | 23.38 | 1.65 | 11.42 |
| Asset Turnover | — | 0.09 | 0.02 | — | — | — | — | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 28.61 | 256.44 | — | — | — | — | 13058.89 |
GBIO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Generation Bio Co. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $7M | $6M | $6M | $6M | $3M | $5M | $2M |
Peer Comparison
Compare GBIO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GBIOYou | $36M | -0.3 | — | — | 100.0% | -715.8% | -91.0% | -63.2% | — |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 PRME | $562M | -2.3 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See GBIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GBIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GBIO vs ARWR
Side-by-side business, growth, and profitability comparison vs Arrowhead Pharmaceuticals, Inc..
Start ComparisonGBIO — Frequently Asked Questions
Quick answers to the most common questions about buying GBIO stock.
What is Generation Bio Co.'s P/E ratio?
Generation Bio Co.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
What is Generation Bio Co.'s ROE?
Generation Bio Co.'s return on equity (ROE) is -91.0%. The historical average is -63.2%.
Is GBIO stock overvalued?
Based on historical data, Generation Bio Co. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Generation Bio Co.'s profit margins?
Generation Bio Co. has 100.0% gross margin and -715.8% operating margin.